NCT01728805 2024-04-25Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCLKyowa Kirin Co., Ltd.Phase 3 Completed372 enrolled 14 charts 1 FDA
NCT00601718 2017-05-25Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell LymphomaUniversity of WashingtonPhase 1/2 Completed29 enrolled 10 charts